Industry News
Biotechnology Industry News
Takeda and Alkermes both took data…
Takeda and Alkermes both took data from their orexin receptor 2 (OX2R)-selective agonists to Singapore this morning as the race to get a new class of narcolepsy drug approved heats up.
Junshi has announced that its…
Junshi has announced that its IL-17 antibody hit the goals of a phase 3 psoriasis trial in China, setting up the biopharma to seek national approval.
BioNTech and its new partner…
BioNTech and its new partner Bristol Myers Squibb have trotted out the first global data for their PD-L1xVEGF bispecific in small cell lung cancer. BioNTech’s chief medical officer, Özlem Türeci, M.D., described the findings as
Servier is souping up its…
Servier is souping up its neurology pipeline with a clinical-stage candidate for a rare genetic disease sourced from U.K. biotech Kaerus Bioscience. The French pharma is offering as much as $450 million for KER-0193, a
Partners Daiichi Sankyo and Merck…
Partners Daiichi Sankyo and Merck & Co. are sharing phase 2 data for their investigational antibody-drug conjugate, findings the partners think will help score accelerated approval in pre-treated small cell lung cancer.
The FDA’s ongoing effort to…
The FDA’s ongoing effort to establish a culture of “radical transparency” saw the agency publish another haul of complete response letters yesterday.
Braveheart Bio has waded into the…
Braveheart Bio has waded into the fight for a heart disease market, paying $65 million upfront for a rival to Bristol Myers Squibb’s Camzyos and Cytokinetics’ aficamten.
BioNTech’s HER2 antibody-drug…
BioNTech’s HER2 antibody-drug conjugate has beaten Roche’s Kadcyla in a phase 3 breast cancer trial, positioning the company’s partner Duality Biologics to seek approval for the candidate in China.
The German pharma giant has found…
The German pharma giant has found a new pipeline leader in David Weinreich, M.D., who is joining the company as global head of R&D and chief medical officer for its healthcare unit. Weinreich, who will
The Food and Drug Administration…
The Food and Drug Administration today announced a plan to publicly release complete response letters at the same time they are issued to sponsoring companies, part of what the agency calls a push toward “radical
Nine months after closing a $450…
Nine months after closing a $450 million fundraise, Atlas Venture is back with another biotech financing vehicle, raising $400 million this time.
AC Immune is reducing its…
AC Immune is reducing its workforce by around 30% and narrowing its pipeline to extend its cash runway by about six months.
Enveda has closed its second $150…
Enveda has closed its second $150 million financing round of the year. The series D round, which moves Enveda’s total funding beyond $500 million, positions the biotech to advance a crop of programs into the
A phase 3 trial of Sanofi’s…
A phase 3 trial of Sanofi’s eczema prospect amlitelimab has hit its primary and key secondary endpoints. Yet, with the data falling short of analyst expectations, shares in the company opened down 9% in Paris.
An interim analysis reported in…
An interim analysis reported in June showed that Amgen's Zai Labs-partnered bemarituzumab made improvements in overall survival, but the final analysis tells a different story.
Gilead Sciences’ Kite Pharma has…
Gilead Sciences' Kite Pharma has cut off a collaboration with Shoreline Biosciences, ending a research collaboration on off-the-shelf cell therapies that was valued at more than $2.3 billion.
After becoming the first group to…
After becoming the first group to therapeutically edit human RNA in October 2024, Wave Life Sciences has released more data from an ongoing alpha-1 antitrypsin deficiency clinical trial—and investors appear less enthused this time around.
The FDA has outlined a new review…
The FDA has outlined a new review process for drugs and biologics designed to treat ultra-rare genetic diseases that would allow a single-arm trial, plus other supportive data, to serve as pivotal evidence.
Treeline Biosciences has surfaced…
Treeline Biosciences has surfaced from secrecy to reveal the harvesting of a $200 million series A extension and the picking of some ripe clinical programs. The extra cash brings the Massachusetts-based oncology outfit’s total funding
Valneva has reported phase 2 data…
Valneva has reported phase 2 data on the third booster dose of its Pfizer-partnered Lyme disease vaccine candidate, ticking off another task for a prospect that could reach regulatory review next year.